(PharmaNewsWire.Com, June 21, 2017 ) Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1) -mediated auto- and alloimmune responses and promotes immunological tolerance.
Report Highlights
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs) -mediated innate immune response.
The report 'Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2017' outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviewsalso reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 4, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Solid Tumor, Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Gastric Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL) , Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Adrenocortical Carcinoma (Adrenal Cortex Cancer) , Bile Duct Cancer (Cholangiocarcinoma) , Blood Cancer, Bone Metastasis, Colon Carcinoma, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST) , Head And Neck Cancer, Hematological Tumor, Kidney Cancer (Renal Cell Cancer) , Leukemias, Liposarcoma, Liver Cancer, Melanoma, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Neuroendocrine Tumors, Non-Rhabdomyosarcoma, Ocular Melanoma, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Peritoneal Cancer, Pheochromocytoma, Recurrent Glioblastoma Multiforme (GBM) , Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Skin Cancer, Thrombosis, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) , Ureter Cancer, Urethral Cancer and Wilms' Tumor (Nephroblastoma) .
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Astellas Pharma Inc BerGenBio ASA Betta Pharmaceuticals Co Ltd Celldex Therapeutics Inc Exelixis Inc Ignyta Inc Les Laboratoires Servier SAS Mirati Therapeutics Inc Ono Pharmaceutical Co Ltd Oribase Pharma Qurient Co Ltd SignalChem Lifesciences Corp Takeda Pharmaceutical Company Ltd Tolero Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Astellas Pharma Inc, H1 2017 Pipeline by BerGenBio ASA, H1 2017 Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017 Pipeline by Celldex Therapeutics Inc, H1 2017 ipeline by Exelixis Inc, H1 2017 Pipeline by Ignyta Inc, H1 2017 Pipeline by Les Laboratoires Servier SAS, H1 2017 Pipeline by Mirati Therapeutics Inc, H1 2017 Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Pipeline by Oribase Pharma, H1 2017 Pipeline by Qurient Co Ltd, H1 2017 Pipeline by SignalChem Lifesciences Corp, H1 2017 Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Pipeline by Tolero Pharmaceuticals Inc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1) , H1 2017 Discontinued Products, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: